Burning Rock Biotech Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast Cancer Treatment

Reuters

09/24

<a href="https://laohu8.com/S/BNR">Burning Rock Biotech</a> Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Burning Rock Biotech Ltd. has announced that its OncoGuide™ OncoScreen™ Plus CDx System has received Manufacturing and Marketing Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for AstraZeneca's capivasertib in breast cancer. This approval, achieved in partnership with Riken Genesis, marks the first for a combination medical device product by the two companies. The CDx System is designed to guide treatment decisions for adult patients with unresectable or recurrent hormone-receptor $(HR)$-positive, HER2-negative breast cancer by detecting PIK3CA, AKT1, and PTEN gene alterations. The system's approval supports patient selection for capivasertib in combination with fulvestrant, aiming to improve precision diagnostics and expand therapeutic opportunities for breast cancer patients in Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569472791"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569472791\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569472791?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 13:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569472791","market":"fut","top_or_hot":-1,"title":"Burning Rock Biotech Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech</a> Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Burning Rock Biotech Ltd. has announced that its OncoGuide™ OncoScreen™ Plus CDx System has received Manufacturing and Marketing Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for AstraZeneca's capivasertib in breast cancer. This approval, achieved in partnership with Riken Genesis, marks the first for a combination medical device product by the two companies. The CDx System is designed to guide treatment decisions for adult patients with unresectable or recurrent hormone-receptor <a href=\"https://laohu8.com/S/HR\">$(HR)$</a>-positive, HER2-negative breast cancer by detecting PIK3CA, AKT1, and PTEN gene alterations. The system's approval supports patient selection for capivasertib in combination with fulvestrant, aiming to improve precision diagnostics and expand therapeutic opportunities for breast cancer patients in Japan.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Burning Rock Biotech Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBurning Rock Biotech Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast Cancer Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-24 13:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech</a> Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Burning Rock Biotech Ltd. has announced that its OncoGuide™ OncoScreen™ Plus CDx System has received Manufacturing and Marketing Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for AstraZeneca's capivasertib in breast cancer. This approval, achieved in partnership with Riken Genesis, marks the first for a combination medical device product by the two companies. The CDx System is designed to guide treatment decisions for adult patients with unresectable or recurrent hormone-receptor <a href=\"https://laohu8.com/S/HR\">$(HR)$</a>-positive, HER2-negative breast cancer by detecting PIK3CA, AKT1, and PTEN gene alterations. The system's approval supports patient selection for capivasertib in combination with fulvestrant, aiming to improve precision diagnostics and expand therapeutic opportunities for breast cancer patients in Japan.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0496365809.HKD","symbol_name":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL7sXyDh:1","article_id":"2569472791","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569472791","pubTimestamp":1758693439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Burning Rock Biotech Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen Plus CDx System as Companion Diagnostic for Breast Cancer Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK5011":"制药","IE00BKPKM643.USD":"NEUBERGER BERMAN EUROPEAN SUSTAINABLE EQUITY \"A\" (USDHDG) ACC","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0526926950.USD":"贝莱德欧洲基金","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0047473722.EUR":"HSBC GIF EUROPE VALUE \"PD\" (EUR) INC","AZN.UK":"阿斯利康制药","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","BNR":"燃石医学","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","LU0882574055.USD":"富达全球健康医疗A ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0823399737.USD":"BNP PARIBAS EUROPE EQUITY \"C\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0499090636.EUR":"AZ FUND 1 DIVIDEND PREMIUM \"A-AZ\" ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU0969580561.USD":"贝莱德欧洲特别时机基金A2","03165":"华夏欧优股对冲","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0047473722.SGD":"HSBC GIF EUROPE VALUE \"PD\" (SGD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H"},"translate_title":"Burning Rock Biotech Ltd.和Riken Genesis获得日本OncoScreen批准™Plus CDx系统作为乳腺癌治疗的伴随诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"BNR":0.9,"AZN.UK":0.9},"content_text":"Burning Rock Biotech Ltd. and Riken Genesis Secure Japan's Approval for OncoScreen™ Plus CDx System as Companion Diagnostic for Breast Cancer Treatment\n\n\n        Burning Rock Biotech Ltd. has announced that its OncoGuide™ OncoScreen™ Plus CDx System has received Manufacturing and Marketing Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for AstraZeneca's capivasertib in breast cancer. This approval, achieved in partnership with Riken Genesis, marks the first for a combination medical device product by the two companies. The CDx System is designed to guide treatment decisions for adult patients with unresectable or recurrent hormone-receptor $(HR)$-positive, HER2-negative breast cancer by detecting PIK3CA, AKT1, and PTEN gene alterations. The system's approval supports patient selection for capivasertib in combination with fulvestrant, aiming to improve precision diagnostics and expand therapeutic opportunities for breast cancer patients in Japan.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}